|Description||HVEM belongs to the TNF Receptor superfamily of transmembrane proteins and plays a role in the activation of T-cells and other lymphocytes. It is expressed in various cells and tissues including spleen, thymus, lung, macrophages, and T-cells. HVEM activation induces a signaling cascade which results in induction of transcription factors NF-kappaB and AP-1. LIGHT (TNFSF14) and TNF-β (TNFSF1) function as the ligands for HVEM, which can also bind specifically to herpes simplex virus glycoprotein D. Soluble HVEM can act as a “receptor decoy” resulting in inhibition of the activity of the HVEM ligands, LIGHT and TNF-β. Recombinant human HVEM-Fc Chimera is a 376 amino acid fusion protein containing an N-terminal domain corresponding to the extracellular region of HVEM and a C-terminal domain corresponding to residues 102 to 330 of human IgG1.|
|BiologicalActivity||Determined by its ability to neutralize 0.25 ng/ml of hTNFβ induced cytotoxicity on murine L929 cells. The expected ED50 for this effect is 1.3-1.9 μg/ml of HVEM-Fc.|
|Authenticity||Verified by N-terminal and Mass Spectrometry analyses (when applicable).|
|Endotoxin||Endotoxin level is <0.1 ng/ µg of protein (<1EU/ µg).|
|Protein Content||Verified by UV Spectroscopy and/or SDS-PAGE gel.|
|Precautions||Recombinant Human HVEM-Fc is for research use only and not for use in diagnostic or therapeutic procedures.|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at email@example.com.